Posters

Impact of severe intraocular lens calcification on the optical quality of segmental multifocal intraocular lenses

Poster Details

First Author: T.Yildirim GERMANY

Co Author(s):    G. Łabuz   R. Khoramnia   H. Son   S. Schickhardt   G. Auffarth        

Abstract Details

Purpose:

To analyse the impact of severe intraocular lens (IOL) opacification on the optical quality of segmental multifocal IOLs, in an in-vitro laboratory study.

Setting:

The David J. Apple International Laboratory for Ocular Pathology, Heidelberg, Germany.

Methods:

Eight hydrophilic segmental bifocal IOLs were exchanged for clear lenses due to dense opacification. Specimens were sent to our laboratory for analysis between February 2017 and August 2018. Sending surgeons provided information about patients’ history. Explants comprised three IOL models, LS-313 MF 30 (4 cases), LS-312 MF 30 (3 cases) and LS-313 MF 15 (1 case). Material analysis was performed exemplary to confirm IOL calcification. Assessment of the optical quality included the modulation transfer function (MTF) and straylight measurement. Values were compared to clear lenses.

Results:

No secondary surgical procedure was found in the patients’ history except for a neodymium:yttrium-aluminum-garnet (Nd:YAG) capsulotomy in one case. Fine granules, stained positive for calcium and phosphorus caused the opacification. Despite dense calcification all but one lens still showed two distinct foci in the MTF measurements. Straylight values were higher than in an average cataract lens (1.52 log(s)) in all cases, with an average value of 2.2 ± 0.16 log(s).

Conclusions:

We describe the first cases of calcification in hydrophilic segmental bifocal IOLs including material analysis and optical quality assessment. Primary IOL calcification had a rather small effect on the MTF in most of the cases but a large impact on straylight levels. Patients suffered from different symptoms of deteriorated visual quality, ultimately necessitating IOL exchange. An IOL exchange always bears the risk of intraoperative complications.

Financial Disclosure:

... receives consulting fees, retainer, or contract payments from a competing company, ... travel has been funded, fully or partially, by a competing company, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a competing company, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a competing company, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented